Viral clearance and viral testing refers to the detection and elimination of viral contaminants, using a wide array of methods, to ensure the product’s safety for human use. Over the past few years, viral clearance and viral testing has emerged as one of the key pre-requisites for biopharmaceutical regulatory approvals. It is worth mentioning that, till date, over 630 biologics have already been approved by the Food and Drug Administration (FDA), while more than 8,000 biopharmaceuticals are in the clinical evaluation process. This increased number of approvals and ongoing clinical trials in the biopharmaceutical industry has resulted in a rise in the demand for such studies. However, virus removal, inactivation and detection requires specialized expertise as it is a complex, cost intensive, and time consuming process. Therefore, innovators are actively exploring avenues that would enable them to overcome the existing challenges. Among other alternatives, outsourcing these studies to service providers having FDA accredited laboratories has emerged as a preferred option for most of the biopharmaceutical manufacturers. Presently, a number of players across the globe are actively engaged in providing efficient viral clearance and viral testing services throughout the research and development process. Further, as more biologics enter into the development pipeline, the market of viral clearance and viral testing services is anticipated to witness a healthy growth.
Key Market Insights
The Viral Clearance and Viral Testing Services Market - Distribution by Scale of Operation (Discovery Phase, Preclinical Phase and Clinical Phase), Method of Viral Clearance and Testing (Viral Detection, Viral Inactivation and Viral Removal), End-User (Biotechnology and Pharmaceutical Companies and Academic / Research Institutes) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035 report features an extensive study of the current market landscape and future opportunity for the players involved in offering services related to viral clearance and testing. The report answers many key questions related to this domain.
Benefits and Growing Demand for Viral Clearance and Viral Testing Services
Viral clearance and testing studies have emerged as a mandatory step for regulatory submissions of biologics for commercial applications. These studies result in streamlined manufacturing of contamination free / safe products and on-time delivery of biologics. Owing to this, the demand for these services has increased significantly. It is worth highlighting that, with the continuous revision of the regulatory guidelines, viral clearance and testing studies are already amongst the most essential steps in the manufacturing of biologics, including antibodies, blood products, cell and gene therapies, hormones, recombinant proteins, therapeutic proteins and vaccines.
Need for Outsourcing Viral Clearance and Viral Testing Studies
The rise of biologics has resulted in an increasing demand for viral clearance and testing studies. However, these studies are quite cost intensive, time-consuming and follow stringent regulatory guidelines. In addition, they require specialized technical skills and good scientific expertise. This has prompted the biopharmaceutical developers to outsource these studies to the service providers, which have aseptic laboratories, GMP-certified facilities and specialized equipment in accordance with the requirements of regulatory authorities.
Current Market Landscape of Viral Clearance and Testing Service Providers
The viral clearance and viral testing service providers landscape features a mix of large, mid-sized and small companies, which have the required expertise to offer various services for the viral clearance and testing of biologics, across the manufacturing and purification stages. It is worth highlighting that majority of the service providers are large companies. Recent developments in this segment of the biopharmaceutical industry indicate that the service providers are upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for these services.
Key Drivers in the Viral Clearance and Viral Testing Services Market
Since the onset of the COVID-19 pandemic, viral clearance and viral testing services for biopharmaceuticals have garnered significant attention. In addition, the success of next-generation sequencing in efficiently detecting a wide variety of viruses has created an enormous need for the consistent usage of such advanced tools / methods in viral clearance and testing studies. In the coming decade, several promising techniques, specifically those exhibiting enhanced efficacy, are anticipated to develop at a faster rate. Moreover, considering the active involvement of large players as well as the new entrants, the viral clearance and testing services market is likely to witness healthy growth. Further, to address the growing demand for these services, various large players have undertaken several initiatives, including strengthening their respective service portfolios, entering into strategic deals, and expanding their facility and capacity.
Market Size of the Viral Clearance and Viral Testing Services Market
Driven by the rising interest in research and development activities and the demand for viral clearance and testing services, the future opportunities and growth associated with this market are anticipated to witness a noteworthy growth in the foreseen future. Specifically, in terms of end-users, the market is anticipated to be driven by biotechnology and pharmaceutical industry. In addition, presently, more than 60% of the market is captured by players based in North America and Europe.
Key Players in the Viral Clearance and Viral Testing Services Market
Examples of key players engaged in this domain (which have also been captured in this report) include Charles River Laboratories, Creative Biolabs, Eurofins Scientific, Microbac Laboratories, MilliporeSigma, Nelson Labs, Syngene International, Texcell, Vironova and WuXi Biologics.
Scope of the Report
The study presents an in-depth analysis of the various firms / organizations that are engaged in this domain, across different segments.
Amongst other elements, the report includes:
- An executive summary of the insights captured during our research. It offers a high-level view on the current state of viral clearance and testing services market and its likely evolution in the mid-long term.
- A general overview of the viral clearance and testing studies, highlighting details on viral contamination in biologics and the need for viral clearance and testing. It also presents information on the process of viral clearance and testing, and regulatory guidelines related to viral contamination. Additionally, it features a discussion on the future perspectives of the viral clearance and testing industry.
- A detailed assessment of the overall market landscape of the companies offering viral clearance and testing services, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, location of viral clearance and testing facilities, type of virus detected (by envelope - RNA enveloped, RNA non-enveloped, DNA enveloped and DNA non-enveloped), type of virus detected (by class - retrovirus, adenovirus, lentivirus, adeno-associated virus (AAV), herpesvirus and others), key offerings (viral clearance services, viral testing services and viral clearance products), type of biologic(s) analyzed (antibodies, cell and gene therapies, vaccines, recombinant proteins, blood and blood products, hormones and others), method(s) of viral clearance (inactivation - pH treatment, solvent detergent, heat pasteurization and others), method(s) of viral clearance (removal - chromatography, filtration, precipitation and others) and type of viral testing service(s) offered (cell bank testing, raw material testing, unprocessed bulk testing and end of production process testing).
- A detailed competitiveness analysis of viral clearance and testing service providers based in North America, Europe and Asia-Pacific. The analysis compares the service providers based on supplier strength (in terms of years of experience and company size) and service strength (considering key offerings, type of virus detected (by envelope), type of virus detected (by class), method(s) of viral clearance (removal), method(s) of viral clearance (inactivation), viral testing service(s) offered, type of biologic(s) analyzed and additional services offered).
- Tabulated profiles of key players based in North America, Europe and Asia-Pacific that are engaged in providing services related to viral clearance and testing (shortlisted based on strength of service portfolio). Each profile includes a brief overview of the company, financial information (if available), information on viral clearance and testing related services, recent developments and an informed future outlook.
- An in-depth analysis of various patents that have been filed / granted for viral clearance and testing, since 2017, based on various relevant parameters, such type of patent, publication year, application year, type of organization, emerging focus areas, geographical location, CPC symbols, leading players (in terms of number of patents granted / filed), patent benchmarking (in terms of CPC symbols and leading players), patent characteristics and patent age. It also includes an insightful patent valuation analysis and list of leading patents by number of citations.
- A detailed analysis of recent developments taking place in this domain. This chapter includes the partnerships inked between stakeholders engaged in this domain, since 2015, covering instances of mergers and acquisitions, service agreements, service alliances, technology assessment agreements and other agreements. Further, it comprises of analysis of the deals inked based on year of partnership, type of partnership, purpose of partnership, type of organization, location of facility, and geographical region. It also highlights the most active players (in terms of number of partnerships) in the domain. In addition, this chapter also includes a detailed assessment of the recent expansion initiatives undertaken by various service providers to enhance viral clearance and testing capabilities, based on various parameters, including year of expansion, type of expansion, focus of expansion, type of service(s) offered, type of biologic(s) involved, and geography. It also highlights the most active players (in terms of number of expansions) in the domain.
One of the key objectives of the report was to estimate the current opportunity and the future growth potential of the viral clearance and testing services market over the coming years. We have provided informed estimates on the likely evolution of the market for the period, 2023-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as scale of operation (discovery phase, preclinical phase and clinical phase), method of viral clearance and testing (viral detection, viral inactivation and viral removal), end-user (biotechnology and pharmaceutical companies and academic / research institutes), and key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.
Frequently Asked Questions
Question 1: What is viral contamination in biopharmaceutical industry?
Answer: Viral contamination is a serious threat to the biopharmaceutical industry; it occurs when the biologics are infected by the endogenous and adventitious viruses, during the production process. The potential sources of these viruses include cell lines, blood, hormones and other animal or human derived unprocessed material.
Question 2: How many players are providing services related to viral clearance and viral testing?
Answer: Presently, more than 30 companies offer various services related to viral clearance and testing, including viral testing services (such as cell bank testing, raw material testing, unprocessed bulk testing and end of production process testing) and viral clearance services (such as several virus inactivation and removal methods). In addition, few service providers offer services for the specialized detection and removal of prions and transmissible spongiform encephalopathies (TSE).
Question 3: How many patents, related to viral clearance and viral testing, have been filed / granted in the last few years?
Answer: More than 260 patents, related to viral clearance and viral testing, have been filed / granted in the last few years. It is worth mentioning that most of the patents have been filed by industry players and are focused on viral removal methods and techniques.
Question 4: What is the partnership and collaboration trend in viral clearance and viral testing services domain?
Answer: Currently, mergers and acquisitions are the most preferred type of partnership models adopted by the stakeholders in this domain. This is followed by service agreements, service alliances and technology assessment agreements.
Question 5: Which segment is likely to have the largest share in the viral clearance and viral testing services market?
Answer: Presently, viral removal dominates the viral clearance and testing services market. This can be attributed to the ongoing innovations and advancements in viral removal techniques, such as chromatography, filtration, and precipitation.
Question 6: What are the recent developments in the viral clearance and viral testing services market?
Answer: Viral clearance and testing service providers have made significant investments to expand their respective capabilities through the incorporation of advanced methods, technologies, and platforms; this is required for attracting a client base across different geographies. In addition, players have also inked a number of partnerships to enhance their expertise, technology and operations portfolio.
Question 7: Which geographical segment has the highest growth rate in viral clearance and viral testing services market?
Answer: Europe is likely to grow at the highest CAGR, during the period 2023- 2035.
Table of Contents
1. PREFACE
1.1. Chapter Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Frequently Asked Questions
1.6. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Viral Contamination in Biologics
3.3. Need for Viral Clearance and Testing
3.4. Process of Viral Clearance and Testing
3.5. Regulatory Guidelines Related to Viral Contamination
3.6. Future Perspectives
4. VIRAL CLEARANCE AND TESTING SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Viral Clearance and Testing Service Providers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters (Region)
4.2.5. Analysis by Location of Viral Clearance and Testing Facilities
4.2.6. Analysis by Type of Virus Detected (by Envelope)
4.2.7. Analysis by Type of Virus Detected (by Class)
4.2.8. Analysis by Key Offerings
4.2.9 Analysis by Type of Biologic(s) Analyzed
4.2.10 Analysis by Method(s) of Viral Clearance (Inactivation)
4.2.11 Analysis by Method(s) of Viral Clearance (Removal)
4.2.12 Analysis by Type of Viral Testing Service(s) Offered
5. COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2 Methodology and Key Parameters
5.3. Viral Clearance and Testing Service Providers in North America
5.4. Viral Clearance and Testing Service Providers in Europe
5.5. Viral Clearance and Testing Service Providers in Asia-Pacific and Rest of the World
6. VIRAL CLEARANCE AND TESTING SERVICE PROVIDERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. Charles River Laboratories
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Viral Clearance and Testing Related Services
6.2.4. Recent Developments and Future Outlook
6.3. Microbac Laboratories
6.3.1. Company Overview
6.3.2. Viral Clearance and Testing Related Services
6.3.3. Recent Developments and Future Outlook
6.4. Nelson Labs (subsidiary of Sotera Health)
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Viral Clearance and Testing Related Services
6.4.4. Recent Developments and Future Outlook
6.5. Pall (subsidiary of Danaher)
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Viral Clearance and Testing Related Services
6.5.4. Recent Developments and Future Outlook
7. VIRAL CLEARANCE AND TESTING SERVICE PROVIDERS IN EUROPE AND ASIA-PACIFIC
7.1. Chapter Overview
7.2. Eurofins Scientific
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Viral Clearance and Testing Related Services
7.2.4. Recent Developments and Future Outlook
7.3. Syngene International
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Viral Clearance and Testing Related Services
7.3.4. Recent Developments and Future Outlook
7.4. Texcell
7.4.1. Company Overview
7.4.2. Viral Clearance and Testing Related Services
7.4.3. Recent Developments and Future Outlook
8. PATENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Viral Clearance and Testing Services Market: Patent Analysis
8.3.1. Analysis by Patent Publication Year
8.3.2. Analysis by Patent Applications
8.3.3. Analysis by Type of Patent and Patent Publication Year
8.3.4. Analysis by Type of Organization
8.3.5. Word Cloud Analysis: Emerging Focus Areas
8.3.6. Analysis by Geography
8.3.7. Analysis by CPC Symbols
8.3.8. Leading Players: Analysis by Number of Patents
8.4. Viral Clearance and Testing Services Market: Patent Benchmarking Analysis
8.4.1. Analysis by Patent Characteristics
8.5. Viral Clearance and Testing Services: Patent Valuation Analysis
8.6. Leading Patents by Number of Citations
9. RECENT DEVELOPMENTS
9.1 Chapter Overview
9.2. Partnerships and Collaborations
9.2.1. Partnership Models
9.2.2. Viral Clearance and Testing Service Providers: List of Partnerships and Collaborations
9.2.3. Analysis by Year of Partnership
9.2.4. Analysis by Type of Partnership
9.2.5. Analysis by Year and Type of Partnership
9.2.6. Analysis by Purpose of Partnership
9.2.7. Analysis by Type of Organization
9.2.8. Analysis by Location of Facility (Country)
9.2.9. Analysis by Location of Facility (Region)
9.2.10. Most Active Players: Analysis by Number of Partnerships
9.2.11. Analysis by Geography
9.2.11.1. Intercontinental and Intracontinental Agreements
9.3. Recent Expansions
9.3.1. Viral Clearance and Testing Service Providers: List of Recent Expansions
9.3.2. Analysis by Year of Expansion
9.3.3. Analysis by Type of Expansion
9.3.4. Analysis by Focus of Expansion
9.3.5. Analysis by Type of Service(s) Offered
9.3.6. Analysis by Type of Biologic(s) Involved
9.3.7. Analysis by Type of Expansion and Biologic(s) Involved
9.3.8. Most Active Players: Analysis by Number of Expansions
9.3.9. Analysis by Geography
10. VIRAL CLEARANCE AND TESTING SERVICES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Viral Clearance and Testing Services Market, 2023-2035
10.3.1. Global Viral Clearance and Testing Services Market: Distribution by Scale of Operation, 2023 and 2035
10.3.1.1. Viral Clearance and Testing Services Market for Discovery Phase, 2023-2035
10.3.1.2. Viral Clearance and Testing Services Market for Preclinical Phase, 2023-2035
10.3.1.3. Viral Clearance and Testing Services Market for Clinical Phase, 2023-2035
10.3.2. Global Viral Clearance and Testing Services Market: Distribution by Method of Viral Clearance and Testing, 2023 and 2035
10.3.2.1. Viral Clearance and Testing Services Market for Viral Detection, 2023-2035
10.3.2.2. Viral Clearance and Testing Services Market for Viral Inactivation, 2023-2035
10.3.2.3. Viral Clearance and Testing Services Market for Viral Removal, 2023-2035
10.3.3. Global Viral Clearance and Testing Services Market: Distribution by End-User, 2023 and 2035
10.3.3.1. Viral Clearance and Testing Services Market for Biotechnology and Pharmaceutical Companies, 2023-2035
10.3.3.2. Viral Clearance and Testing Services Market for Academic / Research Institutes, 2023-2035
10.3.4. Global Viral Clearance and Testing Services Market: Distribution by Key Geographical Regions, 2023 and 2035
10.3.4.1. Viral Clearance and Testing Services Market in North America, 2023-2035
10.3.4.2. Viral Clearance and Testing Services Market in Europe, 2023-2035
10.3.4.3. Viral Clearance and Testing Services Market in Asia-Pacific, 2023-2035
10.3.4.4. Viral Clearance and Testing Services Market in Rest of the World, 2023-2035
11. CONCLUSION
12. EXECUTIVE INSIGHTS
13. APPENDIX 1: TABULATED DATA
14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 2.1. Executive Summary: Overall Market Landscape
Figure 2.2. Executive Summary: Patent Analysis
Figure 2.3. Executive Summary: Recent Developments
Figure 2.4. Executive Summary: Market Sizing and Opportunity Analysis
Figure 3.1. Sources of Viral Contamination
Figure 3.2. Process of Viral Clearance and Testing
Figure 4.1. Viral Clearance and Testing Service Providers: Distribution by Year of Establishment
Figure 4.2. Viral Clearance and Testing Service Providers: Distribution by Company Size
Figure 4.3. Viral Clearance and Testing Service Providers: Distribution by Location of Headquarters
Figure 4.4. Viral Clearance and Testing Service Providers: Distribution by Company Size and Location of Headquarters (Region)
Figure 4.5. Viral Clearance and Testing Service Providers: Distribution by Location of Viral Clearance and Testing Facilities
Figure 4.6. Viral Clearance and Testing Service Providers: Distribution by Type of Virus Detected (by Envelope)
Figure 4.7. Viral Clearance and Testing Service Providers: Distribution by Type of Virus Detected (by Class)
Figure 4.8. Viral Clearance and Testing Service Providers: Distribution by Key Offerings
Figure 4.9. Viral Clearance and Testing Service Providers: Distribution by Type of Biologic(s) Analyzed
Figure 4.10. Viral Clearance and Testing Service Providers: Distribution by Method(s) of Viral Clearance (Inactivation)
Figure 4.11. Viral Clearance and Testing Service Providers: Distribution by Method(s) of Viral Clearance (Removal)
Figure 4.12. Viral Clearance and Testing Service Providers: Distribution by Type of Viral Testing Service(s) Offered
Figure 5.1. Competitiveness Analysis of Viral Clearance and Testing Service Providers in North America
Figure 5.2. Competitiveness Analysis of Viral Clearance and Testing Service Providers in Europe
Figure 5.3. Competitiveness Analysis of Viral Clearance and Testing Service Providers in Asia-Pacific and Rest of the World
Figure 6.1. Charles River Laboratories: Annual Revenues, 2017-9M 2022 (USD Billion)
Figure 6.2. Nelson Labs: Annual Revenues, 2019-9M 2022 (USD Million)
Figure 6.3. Danaher (parent company of Pall): Annual Revenues, 2017-9M 2022 (USD Billion)
Figure 7.1. Eurofins Scientific: Annual Revenues, 2017-9M 2022 (EUR Billion)
Figure 7.2. Syngene International: Annual Revenues, FY 2018-FY H1 2023 (INR Billion)
Figure 8.1. Patent Analysis: Distribution by Type of Patent
Figure 8.2. Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
Figure 8.3. Patent Analysis: Cumulative Distribution of Patent Applications, Pre- 2017-2022
Figure 8.4. Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2017-2022
Figure 8.5. Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2017-2022
Figure 8.6. Patent Analysis: Emerging Focus Areas
Figure 8.7. Patent Analysis: Distribution by Geography
Figure 8.8. Patent Analysis: Distribution by CPC Symbols
Figure 8.9. Patent Analysis: Leading Players
Figure 8.10. Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Symbols)
Figure 8.11. Patent Analysis: Distribution of Patents by Age
Figure 8.12. Viral Clearance and Testing: Patent Valuation
Figure 9.1. Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Figure 9.2. Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3. Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2022
Figure 9.4. Partnerships and Collaborations: Distribution by Purpose of Partnership
Figure 9.5. Partnerships and Collaborations: Distribution by Type of Organization, 2015-2022
Figure 9.6. Partnerships and Collaborations: Distribution by Location of Facility (Country)
Figure 9.7. Partnerships and Collaborations: Distribution by Location of Facility (Region)
Figure 9.8. Most Active Players: Distribution by Number of Partnerships
Figure 9.9. Partnerships and Collaborations: Distribution by Geography
Figure 9.10. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.11. Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Figure 9.12. Recent Expansions: Distribution by Type of Expansion
Figure 9.13. Recent Expansions: Distribution by Focus of Expansion
Figure 9.14. Recent Expansions: Distribution by Type of Service(s) Offered
Figure 9.15. Recent Expansions: Distribution by Type of Biologic(s) Involved
Figure 9.16. Recent Expansions: Distribution by Type of Expansion and Service(s) Offered
Figure 9.17. Recent Expansions: Distribution by Type of Expansion and Biologic(s) Involved
Figure 9.18. Most Active Players: Distribution by Number of Expansions
Figure 9.19. Recent Expansions: Distribution by Geography
Figure 9.20. Recent Expansions: Distribution by Location of Expansion Project
Figure 10.1. Global Viral Clearance and Testing Services Market, 2023-2035 (USD Million)
Figure 10.2. Viral Clearance and Testing Services Market: Distribution by Scale of Operation, 2023 and 2035 (USD Million)
Figure 10.3. Viral Clearance and Testing Services Market for Discovery Phase, 2023-2035 (USD Million)
Figure 10.4. Viral Clearance and Testing Services Market for Preclinical Phase, 2023-2035 (USD Million)
Figure 10.5. Viral Clearance and Testing Services Market for Clinical Phase, 2023-2035 (USD Million)
Figure 10.6. Viral Clearance and Testing Services Market: Distribution by Method of Viral Clearance and Testing, 2023 and 2035 (USD Million)
Figure 10.7. Viral Clearance and Testing Services Market for Viral Detection, 2023-2035 (USD Million)
Figure 10.8. Viral Clearance and Testing Services Market for Viral Inactivation, 2023-2035 (USD Million)
Figure 10.9. Viral Clearance and Testing Services Market for Viral Removal, 2023-2035 (USD Million)
Figure 10.10. Viral Clearance and Testing Services Market: Distribution by End-User, 2023 and 2035 (USD Million)
Figure 10.11. Viral Clearance and Testing Services Market for Biotechnology and Pharmaceutical Companies, 2023-2035 (USD Million)
Figure 10.12. Viral Clearance and Testing Services Market for Academic / Research Institutes, 2023-2035 (USD Million)
Figure 10.13. Viral Clearance and Testing Services Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Figure 10.14. Viral Clearance and Testing Services Market in North America, 2023-2035 (USD Million)
Figure 10.15. Viral Clearance and Testing Services Market in Europe, 2023-2035 (USD Million)
Figure 10.16. Viral Clearance and Testing Services Market in Asia-Pacific, 2023-2035 (USD Million)
Figure 10.17. Viral Clearance and Testing Services Market in Rest of the World, 2023-2035 (USD Million)
Figure 11.1. Concluding Remarks: Overall Market Landscape
Figure 11.2. Concluding Remarks: Patent Analysis
Figure 11.3. Concluding Remarks: Recent Developments
Figure 11.4. Concluding Remarks: Market Sizing and Opportunity Analysis
List Of Tables
Table 4.1. Viral Clearance and Testing Service Providers: Information on Company, Year of Establishment, Company Size, Location of Headquarters and Location of Viral Clearance and Testing Service Facilities
Table 4.2. Viral Clearance and Testing Service Providers: Information on Type of Virus Detected (by Envelope) and Type of Virus Detected (by Class)
Table 4.3. Viral Clearance and Testing Service Providers: Information on Key Offerings and Type of Biologic(s) Analyzed
Table 4.4. Viral Clearance and Testing Service Providers: Information on Method(s) of Viral Clearance (Inactivation), Method(s) of Viral Clearance (Removal) and Type of Viral Testing Service(s) Offered
Table 6.1. Viral Clearance and Testing Service Providers in North America: List of Companies Profiled
Table 6.2. Charles River Laboratories: Company Snapshot
Table 6.3. Charles River Laboratories: Overview of Viral Clearance and Testing Services
Table 6.4. Charles River Laboratories: Recent Developments and Future Outlook
Table 6.5. Microbac Laboratories: Company Snapshot
Table 6.6. Microbac Laboratories: Overview of Viral Clearance and Testing Services
Table 6.7. Nelson Labs: Company Snapshot
Table 6.8. Nelson Labs: Overview of Viral Clearance and Testing Services
Table 6.9. Nelson Labs: Recent Developments and Future Outlook
Table 6.10. Pall Corporation: Company Snapshot
Table 6.11. Pall Corporation: Overview of Viral Clearance and Testing Services
Table 7.1. Viral Clearance and Testing Service Providers in Europe and Asia-Pacific: List of Companies Profiled
Table 7.2. Eurofins Scientific: Company Snapshot
Table 7.3. Eurofins Scientific: Overview of Viral Clearance and Testing Services
Table 7.4. Eurofins Scientific: Recent Developments and Future Outlook
Table 7.5. Syngene International: Company Snapshot
Table 7.6. Syngene International: Overview of Viral Clearance and Testing Services
Table 7.7. Syngene International: Recent Developments and Future Outlook
Table 7.8. Texcell: Company Snapshot
Table 7.9. Texcell: Overview of Viral Clearance and Testing Services
Table 7.10. Texcell: Recent Developments and Future Outlook
Table 8.1. Patent Analysis: CPC Sections
Table 8.2. Patent Analysis: CPC Codes
Table 8.3. Patent Analysis: CPC Symbol
Table 8.4. Patent Analysis: Summary of Benchmarking Analysis
Table 8.5. Patent Analysis: Categorization based on Weighted Valuation Scores
Table 8.6. Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 8.7. Patent Portfolio: List of Leading Patents (by Number of Citations)
Table 9.1. Viral Clearance and Testing Service Providers: List of Partnerships and Collaborations, 2015-2022
Table 9.2. Partnerships and Collaborations: Information on Purpose of Partnership, Type of Organization, Location of Facility (Country) and Location of Facility (Region), 2015-2022
Table 9.3. Viral Clearance and Testing Service Providers: List of Recent Expansions, 2017-2022
Table 9.4. Recent Expansions: Information on Type of Service(s) Offered and Type of Biologic(s) Involved, 2017-2022
Table 12.1. hylabs: Company Snapshot
Table 12.2. WuXi Biologics: Company Snapshot
Table 13.1. Viral Clearance and Testing Service Providers: Distribution by Year of Establishment
Table 13.2. Viral Clearance and Testing Service Providers: Distribution by Company Size
Table 13.3. Viral Clearance and Testing Service Providers: Distribution by Location of Headquarters
Table 13.4. Viral Clearance and Testing Service Providers: Distribution by Company Size and Location of Headquarters (Region)
Table 13.5. Viral Clearance and Testing Service Providers: Distribution by Type of Virus Detected (by Envelope)
Table 13.6. Viral Clearance and Testing Service Providers: Distribution by Type of Virus Detected (by Class)
Table 13.7. Viral Clearance and Testing Service Providers: Distribution by Key Offerings
Table 13.8. Viral Clearance and Testing Service Providers: Distribution by Type of Biologic(s) Analyzed
Table 13.9. Viral Clearance and Testing Service Providers: Distribution by Method(s) of Viral Clearance (Inactivation)
Table 13.10. Viral Clearance and Testing Service Providers: Distribution by Method(s) of Viral Clearance (Removal)
Table 13.11. Viral Clearance and Testing Service Providers: Distribution by Type of Viral Testing Service(s) Offered
Table 13.12. Charles River Laboratories: Annual Revenues, 2017-9M 2022 (USD Billion)
Table 13.13. Nelson Labs: Annual Revenues, 2019-9M 2022 (USD Million)
Table 13.14. Danaher (parent company of Pall): Annual Revenues, 2017-9M 2022 (USD Billion)
Table 13.15. Eurofins Scientific: Annual Revenues, 2017-9M 2022 (EUR Billion)
Table 13.16. Syngene International: Annual Revenues, FY 2018-FY H1 2023 (INR Billion)
Table 13.17. Patent Analysis: Distribution by Type of Patent
Table 13.18. Patent Analysis: Cumulative Distribution by Patent Publication Year, 2017-2022
Table 13.19. Patent Analysis: Cumulative Distribution of Patent Applications, Pre- 2017-2022
Table 13.20. Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2017-2022
Table 13.21. Patent Analysis: Cumulative Year-wise Distribution by Type of Organization, 2017-2022
Table 13.22. Patent Analysis: Emerging Focus Areas
Table 13.23. Patent Analysis: Distribution by Geography
Table 13.24. Patent Analysis: Distribution by CPC Symbols
Table 13.25. Patent Analysis: Leading Players
Table 13.26. Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (CPC Symbols)
Table 13.27. Patent Analysis: Distribution of Patents by Age
Table 13.28. Viral Clearance and Testing: Patent Valuation
Table 13.29. Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2022
Table 13.30. Partnerships and Collaborations: Distribution by Type of Partnership
Table 13.31. Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2022
Table 13.32. Partnerships and Collaborations: Distribution by Purpose of Partnership
Table 13.33. Partnerships and Collaborations: Distribution by Type of Organization, 2015-2022
Table 13.34. Partnerships and Collaborations: Distribution by Location of Facility (Region)
Table 13.35. Most Active Players: Distribution by Number of Partnerships
Table 13.36. Partnerships and Collaborations: Distribution by Geography
Table 13.37. Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 13.38. Recent Expansions: Cumulative Year-wise Trend, 2017-2022
Table 13.39. Recent Expansions: Distribution by Type of Expansion
Table 13.40. Recent Expansions: Distribution by Focus of Expansion
Table 13.41. Recent Expansions: Distribution by Type of Service(s) Offered
Table 13.42. Recent Expansions: Distribution by Type of Biologic(s) Involved
Table 13.43. Recent Expansions: Distribution by Type of Expansion and Service(s) Offered
Table 13.44. Recent Expansions: Distribution by Type of Expansion and Biologic(s) Involved
Table 13.45. Most Active Players: Distribution by Number of Expansions
Table 13.46. Recent Expansions: Distribution by Geography
Table 13.47. Recent Expansions: Distribution by Location of Expansion Project
Table 13.48. Global Viral Clearance and Testing Services Market: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.49. Viral Clearance and Testing Services Market: Distribution by Scale of Operation, 2023 and 2035 (USD Million)
Table 13.50. Viral Clearance and Testing Services Market for Discovery Phase: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.51. Viral Clearance and Testing Services Market for Preclinical Phase: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.52. Viral Clearance and Testing Services Market for Clinical Phase: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.53. Viral Clearance and Testing Services Market: Distribution by Method of Viral Clearance and Testing, 2023 and 2035 (USD Million)
Table 13.54. Viral Clearance and Testing Services Market for Viral Detection: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.55. Viral Clearance and Testing Services Market for Viral Inactivation: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.56. Viral Clearance and Testing Services Market for Viral Removal: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.57. Viral Clearance and Testing Services Market: Distribution by End-User, 2023 and 2035 (USD Million)
Table 13.58. Viral Clearance and Testing Services Market for Biotechnology and Pharmaceutical Companies: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.59. Viral Clearance and Testing Services Market for Academic / Research Institutes: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.60. Viral Clearance and Testing Services Market: Distribution by Key Geographical Regions, 2023 and 2035 (USD Million)
Table 13.61. Viral Clearance and Testing Services Market in North America: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.62. Viral Clearance and Testing Services Market in Europe: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.63. Viral Clearance and Testing Services Market in Asia-Pacific: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Table 13.64. Viral Clearance and Testing Services Market in Rest of the World: Conservative, Base and Optimistic Scenarios, 2023-2035 (USD Million)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 3P Biopharmaceuticals
- Abzena
- Advantar Laboratories (acquired by Eurofins Scientific)
- Advinus Therapeutics (acquired by Eurofins Scientific)
- ICAR-Agricultural Technology Research Institute (ATRI)
- Amgen
- ams Laboratories (acquired by Eurofins Scientific)
- Analytical Lab Group (ALG) (acquired by Element Materials Technology)
- Asahi Kasei Medical
- Astellas Pharma
- Avance Biosciences
- Avomeen (acquired by Element Materials Technology)
- Bayer
- Baxalta (acquired by Takeda Pharmaceutical)
- BioOutsource (acquired by Sartorius Stedim Biotech)
- BioScience Laboratories (acquired by Nelson Labs)
- BSL BIOSERVICE (acquired by Eurofins Scientific)
- Catalent
- Creative Biogene
- Charles River Laboratories
- Clean Cells
- Creative Biolabs
- Cygnus Technologies (acquired by Maravai LifeSciences)
- Danaher
- EAG Laboratories (acquired by Eurofins Scientific)
- Element Materials Technology (Element)
- Eurofins Scientific
- Ferring Pharmaceuticals
- FUJIFILM Diosynth Biotechnologies
- Genentech
- Gibraltar Laboratories (acquired by Nelson Labs)
- hylabs
- Jade Biomedical
- JMI Laboratories (acquired by Element Materials Technology)
- Kedrion Biopharma
- Lonza
- Maravai LifeSciences
- Massachusetts Institute of Technology (MIT)
- Mérieux NutriSciences
- Microbac Laboratories
- MilliporeSigma
- MockV Solutions (acquired by Maravai LifeSciences)
- Nelson Labs (acquired by Sotera Health)
- Pall
- PathoQuest
- PHAST Gesellschaft für Pharmazeutische Qualitätsstandards (acquired by Eurofins Scientific)
- Regeneron Pharmaceuticals
- Roche
- Samsung Biologics
- Sartorius Stedim Biotech
- SGS
- Sinensis Life Sciences (acquired by Eurofins Scientific)
- Sotera Health
- Syngene International
- Texcell
- Thermo Fisher Scientific
- Vironova
- ViruSure (acquired by Asahi Kasei Medical)
- WESSLING Hungary (acquired by Eurofins Scientific)
- WuXi Advanced Therapies
- WuXi Biologics
Methodology
LOADING...
